Bio-Techne Corporation (TECH), headquartered in Minneapolis, Minnesota, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets. Valued at $8.3 billion by market cap, the company specializes in proteins, cytokines, growth factors, immunoassays and small molecules. Companies worth $2 billion or more are generally described as “mid-cap stocks,” and TECH perfectly fits that description, with its market cap exceeding this mark ...

基金表现 - Brown Capital Management小型公司基金在2025年第二季度回报率为8.59% 但落后于罗素2000成长指数11.97%的回报率 [1] - 美国小盘股在经历艰难的第一季度后于第二季度出现反弹 [1] - 业绩不佳主要发生在季度末的最后几周 [1] 重点持仓公司表现 - Bio-Techne Corporation（TECH）被列为2025年第二季度业绩拖累因素之一 [3] - 公司市值为79.73亿美元 专注于为研究和临床诊断市场开发生产生命科学试剂、仪器及服务 [2] - 股价在52周内下跌31.43% 月度回报率为-3.81% 截至2025年9月12日收盘价为51.26美元 [2] 投资组合特征 - 基金建议关注其前五大持仓以了解2025年最佳选股 [1]